Cefepime Hydrochloride Injection shortage
Not a nationwide shortage — Fresenius Kabi has told the FDA it is discontinuing its cefepime hydrochloride injections. The FDA lists this under “To be discontinued” as of Oct 8, 2026: a company stopping its own product. 6 other companies sell the same medicine and have not reported a problem, so your pharmacy may be able to order another company’s version.
Fresenius Kabi is stopping cefepime hydrochloride injection, and the change may be permanent. Other makers that have not reported a shortage still list the same medicine in 1 g and 2 g strengths.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is cefepime hydrochloride still in shortage? — status as of Oct 8, 2026
Still listed as “To be discontinued” as of Oct 8, 2026. Fresenius Kabi is stopping its own version only; 6 other companies still sell the same medicine and have not reported a problem. Your pharmacy may need to order another company’s version.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Feb 10, 2026Currently in shortage2 of 2 products affected.
-
Feb 10, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which cefepime hydrochloride products are affected — by company
Company: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Cefepime Hydrochloride Injection, 2 g | 2 g | — | Discontinuation of the manufacture of the drug. | — |
| To Be Discontinued | Cefepime Hydrochloride Injection, 1 g | 1 g | — | Discontinuation of the manufacture of the drug. | — |
These rows are company reports to the FDA for Cefepime Hydrochloride Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get cefepime hydrochloride? options further down this page.
Why is Fresenius Kabi discontinuing cefepime hydrochloride?
Here's what the FDA report shows for cefepime hydrochloride injection. Fresenius Kabi USA told the FDA it is discontinuing, meaning it is stopping the making of, two of its cefepime products: the 1 g vial (NDC 63323-326-20) and the 2 g vial (NDC 63323-340-20). The FDA lists the status as "To Be Discontinued."
The report doesn't give a specific reason code, and the manufacturer didn't share a public explanation for why it made this decision. It also doesn't include any dates for when the supply will run out. The notes only say the company is ending manufacture of these two products. This report covers only Fresenius Kabi's 1 g and 2 g products, so it doesn't speak for any other company that may make cefepime.
Based on the company-reported reason(s) and notes on file with the FDA for Cefepime Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take cefepime hydrochloride?
Cefepime Hydrochloride Injection is currently listed on the FDA drug-shortage list, and the overall supply risk is rated low.
Both strengths on this record, 1 g and 2 g, are affected. The one company that filed the report, Fresenius Kabi USA, LLC, has no available supply of either strength. However, both 1 g and 2 g are still listed by other companies that did not report a shortage. Every strength you might take has at least one listed source.
The reason given is that Fresenius Kabi is discontinuing manufacture of this product. Because of this, its supply may not return, so this may be a permanent change for that maker. This report reflects only Fresenius Kabi, and other manufacturers may still supply the same medicine.
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for your strength.
- The same medicine is listed from Hikma, Hospira, Sagent, WG Critical Care, and Apotex in 1 g and 2 g. Your pharmacy may be able to get one of these, though it may not be in local stock.
- If your strength cannot be found, ask your prescriber or pharmacist about options, such as a different strength or a clinician-chosen alternative.
- Manufacturer contact numbers are listed on this page for reference. Pharmacies usually handle these calls.
This is general information based on national, manufacturer-reported FDA data. It may not match your local pharmacy's stock, and it is not personal medical advice.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get cefepime hydrochloride?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists cefepime hydrochloride injections is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine from other companies (not reporting a shortage)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from companies that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Cefepime Hydrochloride | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9382-10 |
| Cefepime Hydrochloride | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9383-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | Hospira, Inc. | 00409-9566-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | Hospira, Inc. | 00409-9735-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/20mL | Injection, Powder, For Solution · Intramuscular, Intravenous | Sagent Pharmaceuticals | 25021-0121-20 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/20mL | Injection, Powder, For Solution · Intravenous | Sagent Pharmaceuticals | 25021-0122-50 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | WG Critical Care, LLC | 44567-0130-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | WG Critical Care, LLC | 44567-0131-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | Apotex Corp. | 60505-6144-04 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | Apotex Corp. | 60505-6145-04 |
| Cefepime | CEFEPIME HYDROCHLORIDE 100 g/1 | Injection, Powder, For Solution · Intravenous | SAMSON MEDICAL TECHNOLOGIES LLC | 66288-8100-01 |
Therapeutic equivalents & pricing 25 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Cefepime 1 g | Hospira, | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | WG | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | WG | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | Apotex | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | Apotex | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | Fresenius | 10 vials | $3.731 | AP | Availability likely |
| Cefepime Hydrochloride 2 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride 2 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride And Dextrose 2 g/50mL | B. | 50 ml | — | — | FDA listed |
| Cefepime 1 g/50mL | Baxter | 50 ml | — | — | FDA listed |
| Cefepime 2 g | Hospira, | 10 vials | — | AP | FDA listed |
| cefepime 2 g/20mL | Sagent | 10 vials | — | AP | Discontinued |
| Cefepime 2 g | WG | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | WG | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Apotex | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Apotex | 1 vial | — | AP | FDA listed |
| Cefepime 2 g | Apotex | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Fresenius | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Qilu | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride 1 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride 1 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride And Dextrose 1 g/50mL | B. | 50 ml | — | — | FDA listed |
| cefepime 1 g/20mL | Sagent | 10 vials | — | AP | Discontinued |
| Cefepime 1 g | Apotex | 1 vial | — | AP | FDA listed |
| Cefepime 1 g | Qilu | 10 vials | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of cefepime hydrochloride — that fall in the same broad treatment class (cephalosporin antibiotics - 4th generation) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other anti-infective shortages
Cefepime hydrochloride shortage FAQs
Is cefepime hydrochloride still in shortage?
Which strengths of cefepime hydrochloride are affected?
Which cefepime hydrochloride products are affected?
When will cefepime hydrochloride be available again?
Can I still get cefepime hydrochloride somewhere?
What should I do if I take cefepime hydrochloride?
Still have a question about the cefepime hydrochloride shortage?
Ask a pharmacist about this shortage →View Cefepime Hydrochloride Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.